Novartis' Lescol, Lamisil, Voltaren Emulgel mentioned as OTC switch candidates.
This article was originally published in The Tan Sheet
Executive Summary
NOVARTIS LESCOL LIPID LOWERER MAY BE OTC SWITCH CANDIDATE, Jerry Karabelas, Novartis Pharmaceuticals CEO and head of the company's healthcare operations, suggested at a review of the company's 1997 financial results held in London March 17. "Eventually, it is possible that the HMG-CoAs would convert over to OTC status," Karabelas said, in part because Lescol has "an ideal profile from a safety point of view." He did not specify in which countries an attempt to switch Lescol could be made.
You may also be interested in...
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.
Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.